Valuation: Exelixis, Inc.

Capitalization 1.15TCr 979.46Cr 906.45Cr 853.49Cr 1.59TCr 1,06900Cr 1.62TCr 11TCr 4.16TCr 51TCr 4.31TCr 4.22TCr 1,83000Cr P/E ratio 2026 *
14.5x
P/E ratio 2027 * 11.9x
Enterprise value 1.05TCr 892.24Cr 825.73Cr 777.49Cr 1.45TCr 97TCr 1.48TCr 9.69TCr 3.79TCr 47TCr 3.93TCr 3.85TCr 1,66700Cr EV / Sales 2026 *
4.05x
EV / Sales 2027 * 3.22x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day-2.51%
1 week+0.89%
Current month+3.22%
1 month+7.53%
3 months+0.48%
6 months+16.04%
Current year+1.00%
1 week 43.75
Extreme 43.75
45.56
1 month 40.84
Extreme 40.8375
45.56
Current year 39.71
Extreme 39.71
46.31
1 year 33.76
Extreme 33.755
49.62
3 years 18.08
Extreme 18.08
49.62
5 years 14.87
Extreme 14.87
49.62
10 years 4.21
Extreme 4.2139
49.62
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 69 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Change 5d. change 1-year change 3-years change Capi.($)
-2.51%+0.89%+25.38%+127.14% 1.15TCr
-0.59%+4.53%+28.56%+93.99% 4.98TCr
+0.13%+6.34%+104.09%+28.22% 4.7TCr
-3.00%-4.69%+125.77%+831.47% 3.34TCr
+3.83%+4.74%-1.06%-24.09% 2.42TCr
-1.73%+0.28%+66.42%-34.48% 1.9TCr
-0.28%+1.88%+40.07%-34.68% 1.73TCr
-0.29%+0.22%+58.48%+195.71% 1.63TCr
+1.86%+1.50%-15.36%+1,169.03% 1.53TCr
-1.18%+0.04%+51.78% - 1.47TCr
Average -0.38%+1.48%+48.41%+261.37% 2.48TCr
Weighted average by Cap. -0.37%+2.34%+57.23%+233.05%

Financials

2026 *2027 *
Net sales 258.37Cr 220.1Cr 203.7Cr 191.8Cr 357.25Cr 24TCr 364.57Cr 2.39TCr 935.02Cr 12TCr 969.59Cr 949.04Cr 41TCr 293.09Cr 249.68Cr 231.07Cr 217.57Cr 405.26Cr 27TCr 413.56Cr 2.71TCr 1.06TCr 13TCr 1.1TCr 1.08TCr 47TCr
Net income 80Cr 68Cr 63Cr 60Cr 110.99Cr 7.47TCr 113.27Cr 742.43Cr 290.5Cr 3.59TCr 301.24Cr 294.85Cr 13TCr 98Cr 84Cr 78Cr 73Cr 136.05Cr 9.15TCr 138.84Cr 910.06Cr 356.09Cr 4.39TCr 369.25Cr 361.43Cr 16TCr
Net Debt -102.38Cr -87Cr -81Cr -76Cr -141.56Cr -9.52TCr -144.46Cr -946.87Cr -370.49Cr -4.57TCr -384.19Cr -376.04Cr -16TCr -205.62Cr -175.16Cr -162.11Cr -152.64Cr -284.31Cr -19TCr -290.13Cr -1.9TCr -744.11Cr -9.18TCr -771.62Cr -755.27Cr -33TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Employees
1,077
Date Price Change Volume
10/26/10 44.27 $ -2.51% 29,45,426
09/26/09 45.41 $ +2.74% 18,13,072
08/26/08 44.20 $ +0.48% 26,29,277
07/26/07 43.99 $ +0.02% 23,86,716
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
44.27USD
Average target price
46.83USD
Spread / Average Target
+5.79%

Quarterly revenue - Rate of surprise